USPTO favorable to Ceylad
March 16, 2017The U.S. Patent and Trademark Office (USPTO) has been favorable to Ceylad for the fourth time for production of Allogenic TCR-Deficient CAR-T cells.
USPTO said there was no need to reexamine Ceylad’s U.S. patent for allogenic human primary T-cells.
Ceylad announced this on Thursday, noting that the patent remains valid and enforceable.
“ This patent is key for the players that are developing in the US allogeneic CAR-T cell approaches and it places Celyad in a very good position to optimize the significant potential of its allogeneic platform, either on our own or through strategic collaborations”, said Christian Homsy, CEO of Celyad.
Celyad, a clinical-stage biopharmaceutical company focused on the development of specialized cell based therapies, uses its expertise in cell engineering to target cancer. Celyad’s Natural Killer Receptor based T-Cell (NKR-T) platform has the potential to treat a broad range of solid and hematologic tumors. Its lead oncology candidate, the CAR-T NKR-2, has been evaluated in a single dose escalation Phase I clinical trial to assess the safety and feasibility of CAR-T NKR-2 cells in patients suffering from AML or MM. This Phase I study was successfully completed in September 2016.
THINK ( TH erapeutic I mmunotherapy with NK R-2) is a multinational (EU/US) open-label Phase Ib study to assess the safety and clinical activity of multiple administrations of autologous CAR-T NKR-2 cells in seven refractory cancers, including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma).
